Study: Patent law is good for big pharma because it has no innovators

Featured Story

Study: Patent law is good for big pharma because it has no innovators

July 13, 2014 6:00 am by | 0 Comments

A new study adds some empirical firepower to the idea that poor patent laws are crushing innovation in the technology industry. Researchers from the London School of Economics studied citations…


Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

July 22, 2014 8:57 am by | 0 Comments

LONDON/MUMBAI (Reuters) – Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older…


ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

July 21, 2014 1:41 pm by | 0 Comments

ViaCyte, a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, has filed an Investigational New Drug application with the United States Food and…



Report: Weight-loss drug banned in U.S. still causing life-threatening reactions in UK

Report: Weight-loss drug banned in U.S. still causing life-threatening reactions in UK

July 21, 2014 12:42 pm by | 0 Comments

NEW YORK (Reuters Health) – Use of a diet drug known as DNP has been linked to five deaths in the UK since 2007, according to a new report. The…


Ignyta launches clinical trials for metastatic cancer drug

Ignyta launches clinical trials for metastatic cancer drug

July 21, 2014 12:20 pm by | 0 Comments

US oncology biotech firm Ignyta Inc (NASDAQ:RXDX) said Monday it had begun a Phase I/II study of its oral tyrosine kinase inhibitor, RXDX-101, for the treatment of adults with locally…


Pfizer acquires drug development company with 30+ injectable eye products in the works

Pfizer acquires drug development company with 30+ injectable eye products in the works

July 21, 2014 9:39 am by | 0 Comments

United States-based Pfizer has signed a contract to acquire InnoPharma, a United States-based pharmaceutical development company, it was reported on Friday. The transaction is valued at USD360m. Under the deal,…


Genmab, Janssen prep for third Phase 3 trial of ‘breakthrough’ multiple myeloma therapy

Genmab, Janssen prep for third Phase 3 trial of ‘breakthrough’ multiple myeloma therapy

July 18, 2014 11:47 am by | 0 Comments

Danish biotech group Genmab A/S (CPH:GEN) said Friday that its collaborator Janssen Biotech Inc, part of US Johnson & Johnson (NYSE:JNJ), intends to launch a Phase III study of daratumumab…


Kidney disease patients see benefits from Amgen parathyroid medicine in late-stage trial

Kidney disease patients see benefits from Amgen parathyroid medicine in late-stage trial

July 18, 2014 10:16 am by | 0 Comments

(Reuters) – An experimental drug proved effective in a late-stage study in reducing excess levels of a hormone associated with a serious condition often seen in patients with chronic kidney…



New eye injection from Bayer boosts visual acuity in two-year diabetic macular edema study

New eye injection from Bayer boosts visual acuity in two-year diabetic macular edema study

July 18, 2014 9:00 am by | 0 Comments

Bayer HealthCare, part of German pharma group Bayer AG (ETR:BAYN), reported Friday data from a Phase III study showing that aflibercept solution for injection 2 mg resulted in a sustained…


FDA calls committee to discuss heart risks of testosterone replacement products

FDA calls committee to discuss heart risks of testosterone replacement products

July 17, 2014 3:28 pm by | 0 Comments

(Reuters) – The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy….


BI’s ‘breakthrough’ treatment for idiopathic pulmonary fibrosis may delay lung function loss

BI’s ‘breakthrough’ treatment for idiopathic pulmonary fibrosis may delay lung function loss

July 17, 2014 12:00 pm by | 0 Comments

Boehringer Ingelheim Pharmaceuticals Inc, part of German pharmaceutical group Boehringer Ingelheim, said Wednesday that the US FDA had granted Breakthrough Therapy status to its tyrosine kinase inhibitor (TKI), nintedanib, as…


Gradual cost savings to increase profits is a key piece of Novartis overhaul

Gradual cost savings to increase profits is a key piece of Novartis overhaul

July 17, 2014 11:31 am by | 0 Comments

ZURICH (Reuters) – Swiss drugmaker Novartis (NVS) posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins…


Pfizer’s prophylaxis hemophilia B regimen succeeds in late-stage trial

Pfizer’s prophylaxis hemophilia B regimen succeeds in late-stage trial

July 16, 2014 12:20 pm by | 0 Comments

US Pfizer Inc (NYSE:PFE) said Wednesday that a Phase III trial had achieved the primary objective showing that a prophylaxis regimen of its BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg…


Pfizer in-licenses BCRP assay for preclinical drug development

Pfizer in-licenses BCRP assay for preclinical drug development

July 16, 2014 10:00 am by | 0 Comments

US-based Absorption Systems, focusing on novel test systems for drug transporters, said it had inked a licence agreement with US Pfizer Inc (NYSE:PFE), under which Pfizer will in- license its…


A pill of a different color won’t fly for people taking heart meds

A pill of a different color won’t fly for people taking heart meds

July 16, 2014 7:36 am by | 0 Comments

NEW YORK (Reuters Health) – People are more likely to stop taking their medication after a heart attack if the appearance of their pills suddenly changes without explanation, a new…


Andarix adds second orphan drug designation to Tozaride for pancreatic cancer

Andarix adds second orphan drug designation to Tozaride for pancreatic cancer

July 15, 2014 12:53 pm by | 0 Comments

US Andarix Pharmaceuticals, a developer of anti- cancer targeted peptide therapy, said Tuesday that the US FDA had granted orphan drug status to its lead candidate, Tozaride, as a therapy…